As of 2025-07-15, the EV/EBITDA ratio of Ligand Pharmaceuticals Inc (LGND) is -64.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LGND's latest enterprise value is 2,400.32 mil USD. LGND's TTM EBITDA according to its financial statements is -37.35 mil USD. Dividing these 2 quantities gives us the above LGND EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 13.9x | 13.6x |
| Forward P/E multiples | 19.0x - 37.5x | 27.6x |
| Fair Price | (34.23) - (24.47) | (37.35) |
| Upside | -127.0% - -119.3% | -129.4% |
| Date | EV/EBITDA |
| 2025-07-11 | -61.57 |
| 2025-07-10 | -63.26 |
| 2025-07-09 | -61.93 |
| 2025-07-08 | -58.17 |
| 2025-07-07 | -57.47 |
| 2025-07-03 | -57.89 |
| 2025-07-02 | -57.42 |
| 2025-07-01 | -56.85 |
| 2025-06-30 | -57.43 |
| 2025-06-27 | -57.67 |
| 2025-06-26 | -58.46 |
| 2025-06-25 | -58.48 |
| 2025-06-24 | -59.77 |
| 2025-06-23 | -58.09 |
| 2025-06-20 | -57.63 |
| 2025-06-18 | -57.92 |
| 2025-06-17 | -56.84 |
| 2025-06-16 | -58.11 |
| 2025-06-13 | -56.82 |
| 2025-06-12 | -57.82 |
| 2025-06-11 | -58.31 |
| 2025-06-10 | -57.29 |
| 2025-06-09 | -55.26 |
| 2025-06-06 | -53.45 |
| 2025-06-05 | -52.52 |
| 2025-06-04 | -52.32 |
| 2025-06-03 | -51.57 |
| 2025-06-02 | -51.21 |
| 2025-05-30 | -51.49 |
| 2025-05-29 | -50.83 |
| 2025-05-28 | -50.46 |
| 2025-05-27 | -51.21 |
| 2025-05-23 | -51.19 |
| 2025-05-22 | -51.03 |
| 2025-05-21 | -51.63 |
| 2025-05-20 | -52.90 |
| 2025-05-19 | -53.10 |
| 2025-05-16 | -52.71 |
| 2025-05-15 | -52.15 |
| 2025-05-14 | -52.99 |
| 2025-05-13 | -53.27 |
| 2025-05-12 | -53.66 |
| 2025-05-09 | -52.67 |
| 2025-05-08 | -51.66 |
| 2025-05-07 | -53.26 |
| 2025-05-06 | -52.08 |
| 2025-05-05 | -53.64 |
| 2025-05-02 | -55.21 |
| 2025-05-01 | -55.09 |
| 2025-04-30 | -55.45 |